Drugs / Norovirus GI.1/GII.4 Bivalent VLP Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02661490 | Feb → Oct 2016 | norovirus infectious disease | Takeda | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Norovirus GI.1/GII.4 Bivalent VLP Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02661490 ↗ |
| Modality | Vaccine | “Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection” NCT02661490 ↗ |
| Route | Intramuscular | “for IM injection” NCT02661490 ↗ |